Introduction
Constipation is a common problem in patients with advanced cancer and a significant source of major morbidity and distress, which is often under-appreciated [1] . Constipation is subjectively experienced by the patient and diagnostic criteria do not always clearly express the diversity of factors, which may lead to constipation as a clinical problem [2] . Widespread use of opioid analgesics for cancer pain poses specific challenges for patients [3] . Despite its clinical impact, constipation is both poorly recognised and poorly treated. Oncologists must be familiar with the common causes of constipation among cancer patients and the strategies to evaluate and manage this distressing symptom. This European Society for Medical Oncology (ESMO) Clinical Practice Guideline (CPG) is directed towards adult cancer patients experiencing constipation as a consequence of their cancer diagnosis or treatment. The CPG makes specific reference to the context of opioid-induced constipation (OIC), highlights the impact of constipation and offers strategies for pharmacological and non-pharmacological management, as well as the specific challenges in the management of older patients with cancer at enhanced risk of constipation.
Definition
Constipation is defined as the slow movement of faeces through the large intestine, resulting in infrequent bowel movements (BMs) and the passage of dry, hard stools [4] . Constipation is a symptom, not a disease. Although usually temporary, it can impact significantly on quality of life.
The standard clinical definition of chronic (sometimes termed functional) constipation (CC), based on the Rome III criteria [5] , requires the presence of any two of the following symptoms for at least 12 weeks in the previous 12 months (not necessarily consecutively):
• straining during BMs;
• lumpy or hard stool;
• sensation of incomplete evacuation;
• sensation of anorectal blockage or obstruction;
• manual evacuation procedures to remove stool;
• < 3 BMs per week.
The description and definition of constipation given here reflects a broader patient cohort experiencing CC as a clinical problem, not solely a cancer population, although the assessment and treatment are similar across both chronic disease and cancer populations. The experience of constipation is highly subjective and, therefore, two further aspects should be taken into consideration: (i) measurable objective symptoms, including individual stool characteristics and frequency of defaecation; (ii) patient perception, level of discomfort and ease of defaecation [6] . The Rome IV criteria for functional gastrointestinal disorders (FGIDs) published in 2016 has seen the addition of OIC to the section on Bowel Disorders, defined as 'constipation triggered or worsened by opioid analgesics' [7] . The clinical presentation of OIC is similar to other FGIDs and requires differential diagnosis and management.
Pathophysiology of constipation
Functioning normally, the colon absorbs fluids and transports waste to the rectum through the repetitive and periodic contractions of peristalsis, mediated principally by serotonin or 5-hydroxytryptamine (5-HT). Sodium is actively reabsorbed through active transport channels; water through osmosis. Colonic secretion is mediated through chloride channels and results in a net reabsorption of electrolytes and fluids. The rectum eventually distends, resulting in the urge to defaecate and associated contractions via the rectal sphincter. The average colonic transit time is 20-72 hours.
Constipation represents a disruption of these normal mechanisms. Causes may be primary (colonic or anorectal dysfunction) or secondary (disease-or medication-related). Factors contributing to constipation may include disruption of normal motility, excessive dryness of faecal content, diminished perception of rectal distension with loss of urge to defaecate and dysfunction of the rectal sphincter. The longer the stool remains in the colon, the drier it becomes. OIC occurs following titration or increased dosage of opioid medication affecting opioid receptors in the gastrointestinal tract.
Prevalence
The reported prevalence of constipation in advanced cancer patients ranges between 40% and 90% [2, 3] ; more common in the opioidtreated population [8, 9] . Prevalence increases with age and the elderly are five times more prone to constipation than young people, due to polypharmacy, reduced mobility, reduced hydration and reduced urge to defaecate [10] . In older cancer patients receiving palliative care, constipation is one of the most prevalent symptoms, with prevalence rates ranging between 51% and 55% [11] [12] [13] .
Impact and burden of care
Constipation is a major cause of distress for patients with cancer [14] . Constipation may be complicated by development of nausea, vomiting, haemorrhoids, anal fissure, bowel obstruction and urinary retention [8] . Untreated constipation places a burden on the healthcare system, with a need for increased nursing hours and a higher risk of hospitalisation. Prevention of constipation, screening for its presence and early intervention may reduce both patient distress and care costs [15, 16] .
Causes and contributing factors
Among cancer patients, common precipitating factors may be classified as organic or functional. Organic contributing factors commonly include medications (especially opioids, vinca alkaloids, 5-HT3 antagonist antiemetics, iron and antidepressants), metabolic aberrations (particularly dehydration, hypercalcaemia, hypokalaemia and uraemia), neuromuscular dysfunction (autonomic neuropathy and myopathy), structural issues (abdominal or pelvic mass, radiation fibrosis) and pain. Functional factors would include, for example, age, poor food and fluid intake and lack of privacy when toileting (Table 1) [17, 18] .
Information regarding the most frequent medications responsible for constipation among cancer patients derives from smallscale studies and expert review (Table 2) .
Evidence
A search of databases (last search, March 2018) including Medline (through Pubmed), Cochrane CENTRAL, EMBASE, CINHAL and SCOPUS was undertaken. No date restriction was applied. Search terms, using Boolean operators were: 'constipation' AND 'cancer' OR 'advanced cancer' OR 'palliative care' OR 'hospice care' AND 'opioid-induced constipation' AND 'management' AND 'pharmacology' AND 'non-pharmacology'. The search prioritised evidence from systematic reviews of randomised, controlled trials (RCTs), including meta-analyses and RCTs in cancer populations. However, as there is limited evidence in this area, as appropriate, we considered evidence derived from other study designs and from studies in other populations. A manual screening of retrieved articles was then undertaken to identify further studies to inform the guideline. Studies were reviewed by two authors for quality inclusion and agreed by the expert panel. High quality studies which focused on constipation but not cancer were reviewed and only included if clear extrapolation of findings to a cancer population were evident in the expert opinion of the authors. Studies from 2015 to present day reported an increased focus on new and innovative pharmacological treatments and the search was then extended to include these new treatments ('methylnaltrexone' AND 'naloxegol' AND 'naldemedine') in combination with original search terms. These were then included in the overall review of evidence.
Range of evidence. Although there is a significant body of literature which looks to the pharmacology of CC management, best clinical practice, and more recently cost-effectiveness [17] [18] [19] [20] , the focus on cancer is limited. The scope of studies identified either provided descriptive pharmacological management of constipation related to a specific treatment or the comparison of pharmacological treatments versus placebo. There is a growing body of literature to support the use of peripherally acting mu opioid receptor antagonists (PAMORAs) in the efficacy of laxation reported here [21] [22] [23] [24] [25] . In some studies, the constipation was a secondary focus for the study (where, for example, the primary outcome was pain management). There is evidence of high quality reviews with multiple trials regarding CC [26] from which recommendations for oncology practice may be derived. However, extrapolating these results to an advanced cancer or palliative care population is problematic, where comorbidity, frailty and trajectory towards decline may impact negatively on outcomes and effectiveness. The evidence presented here reflects that context in terms of the CPG and recommendations made arising out of evidence reviewed. Overall, based on the limited scope of high-quality trials and meta-analyses in advanced cancer, the expert group considered the quality of evidence for the management of constipation in patients with cancer to be low and largely based on expert opinion, pharmacological reviews and clinical case reports.
Review of evidence. A 2011 Cochrane systematic review [21] building on an earlier review from 2006 looked at the effectiveness of laxatives versus methylnaltrexone in the management of constipation in palliative care patients. Seven studies with 616 participants were identified. Two had a crossover design, and three were multicentre. All patients had advanced disease, and most (but not all) had cancer. Four studies looked at the use of lactulose, senna, co-danthramer, misrakasneham and magnesium hydroxide with liquid paraffin. Three reported on methylnaltrexone use. Comparisons were between laxative therapy and methynaltrexone versus placebo. The evidence for the use of laxatives was inconclusive. Studies on methylnaltrexone reported on 227 patients and demonstrated that, in comparison to placebo, patients had significantly improved laxation within 4 hours, with only one serious adverse event (AE) reported. Good quality RCTs were poor and, although subcutaneous methylnaltrexone was considered efficacious, further larger and more rigorous independent trials were needed. A development of this review in 2015 [22] only considered the laxatives noted above but included docusate in the evaluation. The primary outcome was laxation response and secondary outcomes were patient preference and relief of other symptoms associated with cancer. Five studies (N ¼ 370) were reviewed; all focused on an advanced cancer population, and two had a crossover study design. Laxatives were either compared or reported as a placebo versus laxative. Studies reviewed had small samples sizes and, in some cases, weak methodology, including being under-powered and no clear evidence of blinding. Attrition was high (> 50%) but not unusual given the population. As there were very few RCTs, it was not possible to show effectiveness or benefit of one treatment over another. A noted recommendation is that data from populations beyond palliative care cannot easily be extrapolated and that the nature of palliative care treatment and care may impact on laxative effect.
Opioid-induced constipation: OIC is the most common AE of opioid analgesic therapy in all populations including those with cancer. OIC incidence ranges between 40% and 60% and is variable due to dose and type of opioid used. Opioid analgesics act on mu receptors widely distributed in the gastrointestinal tract, resulting in reduced peristalsis and fluid secretion, increased fluid We also identified one very recent mixed-treatment comparison network meta-analysis of RCTs across a range of interventions to manage OIC [23] . The primary outcome was the number of patients reporting a rescue-free bowel movement (RFBM). Secondary outcomes were time to first laxation, AEs and changes to opioid analgesic activity. They identified 23 studies which formed part of a qualitative synthesis and 21 which were quantitatively examined using a network meta-analysis approach. In the meta-analysis, no clinical trial that specifically targeted cancer patients was identified, although six studies [24] [25] [26] [27] [28] [29] included a cancer population with other groups and one study focused on constipation in cancer [30] . Medications reviewed included lubiprostone, naldemedine, naloxegol, alvimopan and oral and subcutaneous methylnaltrexone. All were more effective than placebo for RFBM. Subcutaneous methylnaltrexone was more effective than oral preparations and in relation to other medications reported, and showed no improvement regarding background pain using opioids. Although the quality of evidence is reported as low or very low, the meta-analysis concluded that subcutaneous methylnaltrexone was safe and effective for OIC.
Methylnaltrexone: Methylnaltrexone is a quaternary derivative of naltrexone, approved by the European Medicines Agency (EMA) for use in the treatment of OIC in advanced illness and palliative care patients whose response to usual laxative therapy has been insufficient. It does not cross the blood-brain barrier and, as a result, it antagonises only peripherally located opioid receptors while sparing centrally mediated analgesic effects of opioid pain medications. There is evidence of predictable effectiveness after subcutaneous administration (initially once every other day), with most patients achieving defaecation within 90 minutes of administration [II, B] [24, 25, 31, 32] . The frequency of administration can be increased, if needed, to once daily.
A review and meta-analyses of methylnaltrexone in OIC [33] for both objective and subjective efficacy and safety outcomes identified seven trials [N ¼ 1860], four specifically with cancer patients, where methylnaltrexone was the drug studied and OIC the primary outcome. Secondary outcomes included time to laxation, patient-reported outcome measures (PROMs) and impact of burden and distress. In each case, methylnaltrexone was compared with placebo. The meta-analyses demonstrated a higher stool frequency and less time to laxation in patients receiving methylnaltrexone. Better patient outcomes and less distress were also associated with methylnaltrexone use. AEs were minimal with only a 0.2% incidence reported. The review concluded that methylnaltrexone is a safe and effective treatment in OIC.
This supports a later exploratory single arm, single dose phase II trial; subcutaneous methylnaltrexone to address severe OIC in cancer patients [34] was given to 12 patients presenting with a prognosis of 3 months and OIC with 3 laxations in the preceding week. The primary endpoint was a rescue-free laxation 4 hours after single dose treatment. Secondary endpoints included rescue-free laxation within 24 hours following treatment, laxation with or without laxatives at 48 hours, overall pain scores, assessment of laxation and patient satisfaction scores. Four patients (33.3%) had an RFBM after 4 hours, five (41.7%) after 24 hours and 10 (83.5%) achieved laxation within 48 hours. Despite reported recruitment difficulties which led to the small sample, authors conclude that methylnaltrexone is effective and well-tolerated by patients.
An earlier double-blind RCT of fixed-dose methylnaltrexone [35] was conducted in patients with advanced illness and OIC. Patients were randomised to subcutaneous injection of methylnaltrexone (8 mg or 12 mg by body weight, n ¼ 116) or placebo (n ¼ 114) every other day for two weeks. Those completing the RCT were eligible to go on to an open label extension of the study (n ¼ 149). The primary endpoint of interest was the percentage of patients with an RFBM with 2 of 4 doses in the first week. Of the methylnaltrexone group, 62.9% achieved the primary endpoint versus 9.6% of those taking placebo. Median laxation of the methylnaltrexone group was 0.8 hours as opposed to 23.6 hours in the placebo group. The open label study results were consistent with the RCT in terms of safety and efficacy, and methylnaltrexone was considered effective and well-tolerated by the patient cohort.
One study already noted [24] specifically focused towards cancer reported 133 patients described as having advanced illness, currently stable on their opioid and laxative regime and randomly assigned to receive a subcutaneous injection of methylnaltrexone at 0.15 mg/kg of body weight versus placebo, every other day for 2 weeks. Co-primary endpoints were defined as laxation within 4 hours after first dose and laxation within 4 hours after 2 of the first 4 doses. Of the intervention group, 48% experienced laxation within 4 hours as opposed to only 15% in the placebo group, while 52% reported laxation within 4 hours of 2 of the first 4 doses, with only 8% reporting the same response in the placebo group. Treatment did not appear to impact analgesic response or to precipitate opioid withdrawal.
Naloxegol: Naloxegol was the first orally dosed PAMORA indicated for the treatment of OIC [36, 37] . It is approved by the EMA for adults who have not responded adequately to previous treatment with laxatives. Based on the mechanism of action, the benefit for cancer patients with OIC is not expected to be different, and the EMA licence for naloxegol includes cancer patients. The recommended dose is 25 mg once daily which can be reduced to 12.5 mg daily in case of abdominal cramps or other AEs [29] .
This phase II double-blind, randomised, placebo-controlled, dose-escalation study [29] evaluated efficacy, tolerability and safety of naloxegol in patients with OIC. Two-hundred and seven patients with 3 BMs per week were randomised to a 4-week trial of naloxegol (5, 25 or 50 mg in sequential cohort following 1-week placebo) versus placebo. The primary endpoint was median change in spontaneous BMs (SBMs) in 1 week. A positive response to dosage at 25 and 50 mg versus placebo was reported. Increase in SBMs was maintained over 4 weeks. AEs were described as transient (e.g. nausea, abdominal pain and diarrhoea), although these did increase in severity relative to higher doses. The outcome of the study was that naloxegol improves the frequency of SBMs with minimal AEs.
A large study undertaken with a non-cancer population (but with relevance to advanced cancer and palliative care) [38] presented two identical phase III double-blind studies (termed studies 4 and 5) to evaluate the efficacy and safety of naloxegol for the treatment of OIC. Using a population of opioid-dependent, noncancer patients (N ¼ 652; study 4 and N ¼ 700; study 5), patients were assigned to receive 12.5 or 25 mg of naloxegol or placebo over a period of 12 weeks. The primary endpoint was noted as 3 BMs for 9 out of 12 weeks and for 3 BMs in the last 4 weeks of the intention-to-treat group. The study also reported response rate in the subpopulation of those who had inadequate laxative response before being enrolled to the study, time to first SBM and number of days per week, with 1 SBMs as secondary endpoint.
Results demonstrated a significantly higher response with 25 mg of naloxegol than with placebo. The studies concluded that naloxegol led to a higher rate of treatment response compared with placebo, with no loss of opioid-mediated analgesia. As such, outcomes of this study are relevant to a palliative care population, given the likelihood of need for opioid analgesia and concomitant constipation treatment to manage symptoms.
This study was later further reported in a pharmaceutical industry report on the pooled analysis of data from the two studies that supported the assertion of the benefit of naloxegol in the treatment of OIC [39] .
Naldemedine: Naldemedine, a more recent PAMORA, has been the subject of phase II and III trials. Two recent studies [30, 40] report on a phase IIb and III trials, respectively, to determine the dose and safety of naldemedine with cancer patients experiencing OIC.
The phase IIb study [30] involved a randomised double-blind multicentre trial to assess efficacy and safety of naldemedine. Two-hundred and twenty-seven patients were randomly assigned to once daily oral naldemedine (at 0.1, 0.2 or 0.4 mg) or placebo (n ¼ 56 in each group). The primary endpoint was a change in SBMs per week from baseline including response rate, change from baseline, change in straining at stool and evidence of complete evacuation. A positive change in SBMs was reported at all doses of naldemedine in comparison with placebo. Change of SBMs with respect to reduction of straining was noted to be significant when doses of 0.2 and 0.4 mg were taken. Diarrhoea was a notable AE reported in the naldemedine group.
Based on these results, a phase III study [40] was undertaken. This study included a 12-week open label extension study as well as a 2-week, randomised double-blind placebo-controlled trial termed COMPOSE-4 and COMPOSE-5. In the COMPOSE-4 study, 193 patients were randomly assigned to a once-daily dose of 0.2 mg naldemedine (n ¼ 97) or placebo (n ¼ 96). The primary endpoint was recorded as an increase in SBMs per week from baseline. The COMPOSE-5 study focused specifically on safety. The COMPOSE-4 study demonstrated a 74% SBM response rate in the intervention group as opposed to placebo (34.4%). The intervention group also reported a change from baseline in terms of SBMs and reduction of straining at stool. Higher levels of AEs (e.g. diarrhoea) were reported in the intervention group but were also reported frequently in the COMPOSE-5 study. It was concluded that 0.2 mg naldemedine was effective to manage OIC and was generally well-tolerated.
Prolonged-release oxycodone-naloxone: The use of a prolongedrelease (PR) combination formulation of oxycodone and naloxone is also increasingly evident in practice [41] . Tertiary amines including naloxone have been shown to restore laxation when opioid therapy is used. PR oxycodone/naloxone versus PR oral oxycodone alone was reported in a double-blind placebo-controlled trial [41] evaluating both analgesia and bowel function. Two-hundred and two opioidstable patients (mainly non-cancer), taking 40-60 mg oxycodone daily, were randomised to either naloxone (10-40 mg daily) or placebo. The Bowel Function Inventory (BFI) was used to assess constipation. Patients taking a combined oral therapy reported significant improvements in bowel function compared with those only taking PR oral oxycodone, with no loss of analgesic efficiency. This outcome has been supported in a more recent review of literature of clinical trials and observational studies into the evidence for PR oxycodone/naloxone treating moderate-to-severe pain and specific impact on opioid-induced bowel dysfunction (OIBD) [42] . Thirty-eight clinical trials and observation studies were reported of which seven were undertaken with a cancer population [43] [44] [45] [46] [47] [48] [49] [50] . Other studies reported on patient groups with direct relevance to patients with cancer (e.g. those with neuropathic pain, pain in the elderly and patients with pain and refractory laxatives symptoms) [42] . Although the method of review is not explicit, the range of evidence presents PR oxycodone/naloxone as an effective treatment of moderate-to-severe pain and effective OIC bowel management for patients unresponsive to normal laxative therapy.
Although these studies demonstrate a growing body of evidence, particularly in relation to therapies to manage OIC, the overall impact remains relatively small in terms of application to clinical practice, and further studies are needed to support these early data. Some of the study outcomes reported here do include an advanced cancer population. However, although the use of PAMORAs is evident in practice, the recommendation would be that they should be used in patients who have not responded successfully to laxative intervention.
Assessment and diagnosis
All cancer patients should be evaluated for constipation [V, B] . In patients with advanced cancer, underlying causative factors for 
deterioration in bowel patterns, regardless of whether or not the patient is receiving treatment [2] .
A full medical history will assist in identifying causes of constipation and should elicit key facts when constipation is suspected (Table 3) [2] .
Assessment should include questions to determine possible causes for constipation including:
• eating and drinking habits;
• medication use (medically prescribed and purchased 'over the counter'); • level of physical activity (relative to stage of illness);
• pre-existing irritable bowel syndrome or diverticular disease;
• other comorbid disease (e.g. heart failure, chronic pulmonary airway disease); • environmental factors (e.g. lack of privacy, assistance needed, bed bound).
The evidence for this arises from consensus expert review and national guidelines [2, 51] but is considered sufficient to make recommendations for best practice [V, B] .
Physical assessment includes abdominal examination [auscultation, perineal inspection and digital rectal examination (DRE)] [V, B]. DRE is a safe and simple, diagnostic tool which may have particular benefit in advanced disease [52] . Table 4 presents the rationale for basic physical assessment.
If constipation is considered part of a spinal cord compression syndrome, full neurological examination is essential, including assessment of anal sphincter tone (lax with colonic hypotonia) and rectal sensation. Again, although derived from expert review, clinical examination including DRE is generally recommended in practice [2, 53] .
Investigations
Investigations are not routinely necessary. If suspected clinically, corrected calcium levels and thyroid function should be checked. More extensive investigation is warranted for those with severe symptoms, sudden changes in number and consistency of BMs or blood in the stool, and for older adults relative to their health and stage of disease.
Assessment scales for constipation
A number of cancer and palliative care symptom assessment scales include a constipation intensity numerical rating scale [54] [55] [56] [57] [58] [59] [60] . Specific constipation assessment scales have been shown to have benefit in advanced disease, notably the Victoria Bowel Performance Scale (BPS) and the Constipation Assessment Scale (CAS) [61, 62] as well as those which use images, such as the Bristol Stool Form Scale, with good clinical utility [2, 63] .
Consensus recommendations from a multidisciplinary exert panel of the American Academy of Pain Medicine [62] BFI and SSS had best utility, although PAC-SYM and BFI were most commonly used. The BF-Diary had specific resonance to OIC, but the panel concluded that the psychometrically validated BFI was less complex and therefore more favourable to use in practice. Consensus was also reached on when to prescribe medication to address OIC, based on symptom severity as indicated by the tool. They concluded that prescription should be introduced for a patient with a BFI score 30 points and no response to initial laxative therapies.
In general, due its subjective nature, PROMs are a preferred aspect of clinical assessment of constipation [64, 65] . However, beyond the one study noted above [62] , no large-scale studies were identified, and further studies are needed to determine optimal tools for practice. As noted in recommendations below, although evidence is limited, best practice would indicate strong clinical benefit to utilising constipation assessment tools in conjunction with PROMs for best outcome [V, B].
We identified one prospective cross-sectional study to assess the correlation between use of the CAS and a plain abdominal X-ray in an advanced cancer population (N ¼ 50), in a palliative care unit. All patients were given an abdominal X-ray, and the extent of faeces was then scored on a scale of 0-12. Three palliative care physicians then independently scored the X-ray, and the Kendall Tau Correlation Coefficient was used to estimate and test correlations. No concordant correlation was found between physicians' CAS and independent radiological scores, nor their CAS score and combined physician radiology scores, with only a moderate correlation overall in physician radiological scores. Therefore, in the absence of any strong correlation, the authors of the study recommended that optimal clinical assessment should include radiological examination [V, C] [66] . However, we conclude that evidence currently remains limited, with only one small study and one expert opinion (as a Letter to the Editor) noted [67] , and that further quality studies are needed.
Recommendations:
• All cancer patients should be evaluated for constipation [V, B]. 
Management Overall principles for management
Best practice is based on a balance between strategies for prevention and self-care and prescribed oral and rectal laxative therapy [V, B] . Approaches may differ between those undergoing oncological therapy and those receiving palliative care alone. Care should be taken, where possible, to avoid drug interaction between anticancer therapy and constipation treatments [68, 69] .
Prevention and self-care strategies (non-pharmacological approaches)
Healthcare professionals should encourage and promote changes in the patient's lifestyle or other underlying factors that may prevent or reduce constipation. Preventative measures should be ongoing throughout a patient's care. Key factors for prevention and self-care to prevent or reduce risk are listed in Table 5 . Of note, lifestyle factors alone have a positive but limited influence on constipation and should not be the sole focus of management [2] . As disease progresses and health deteriorates, lifestyle factors may become less important in clinical management. We did not identify any studies on non-pharmacological approaches with cancer populations. There is some evidence that abdominal massage can be efficacious in reducing gastrointestinal symptoms and improving bowel efficiency, particularly in those patients with concomitant neurogenic problems [II, B] [70] but not in a cancer population. A multicentre randomised superiority trial to compare abdominal massage against no massage was conducted in a sample of multiple sclerosis patients who had neurogenic bowel dysfunction (NBD). Patients (N ¼ 30) were randomly assigned to an intervention group, where the caregiver carried out a daily abdominal massage over 4 weeks versus a control group of bowel management advice only. Patients were asked to complete the Constipation Scoring System (CSS), the NBD score and to keep a bowel diary. Scores were taken at baseline, at week 4 and at week 8; the NBD score was taken also at week 24.
Both groups showed a decrease in constipation between weeks 0 and 4 based on the CSS. However, the extent of improvement was significantly greater in the massage group than in the control group.
A more recent pilot RCT [II, B] [71] also looked at the use of massage in patients with Parkinson's disease, a patient group more recently seen by palliative care specialists. Thirty-two patients from three movement disorder clinics were randomised to either a 6-week daily abdominal massage plus a lifestyle constipation management programme (n ¼ 16) or to a control group (n ¼ 16) who received lifestyle management only. Data were collected at baseline, week 6 (post intervention) and at week 10 using a bowel diary, the Gastrointestinal Rating Scale and the scales used in the multiple sclerosis study described above (i.e. the NBD score and CSS) and qualitative analysis of patient and caregiver interviews. Massage was largely administered by a caregiver. Results demonstrated that those who received both massage and lifestyle support had a better laxation outcome than those receiving lifestyle advice alone. The practice of massage was considered efficacious and, therefore, of added benefit to patients. These are small-scale studies with no evident application to cancer patients. Without further evidence, they are currently considered to be of limited value to standard laxative management and lifestyle factors to manage constipation in those with advanced illness.
In terms of other non-pharmacological therapies, we did not find any studies with sufficient evidence relative to an advanced illness population.
Laxative use, choice and rationale
Judicious use of laxatives is often essential in the prevention and relief of constipation. There is limited evidence to support the use of one laxative over another [19, 20, 22, 32] . Recommendations for patients with advanced cancer regarding the selection of laxatives are proposed in Table 6 , noting those which are generally preferred in clinical practice [V, B] .
Use of suppositories and enemas
Suppositories and enemas are a preferred first-line therapy when DRE identifies a full rectum or faecal impaction [V, B] [2, 63] . Suppositories and enemas may be perceived as a more invasive option by patients. Enemas (such as hyperosmotic saline) and suppositories increase water content and stimulate peristalsis to aid in expulsion, and both work more quickly than oral laxatives.
Suppositories. Suppositories containing glycerine, bisacodyl oxyphenisatin (veripaque) and CO 2 -releasing compounds are all stool softeners and stimulants for rectal motility. They are commonly used for short-term treatments and are often effective. We found no evidence that treatment of constipation with suppositories has been studied in patients with cancer. One Cochrane systematic review has reported on the effectiveness of CO 2 -releasing Table 5 . Key factors for prevention and self-care in the management of constipation Ensuring privacy and comfort to allow a patient to defaecate normally Positioning (to assist gravity, a small footstool may help patient exert pressure more easily) Increased fluid intake Encourage activity and increased mobility within patient limits (even bed to chair) Anticipatory management of constipation when opioids prescribed Advise against home remedies or 'over the counter' or online products which may impact treatments Annals of Oncology Clinical Practice Guidelines suppositories on adults with central neurological dysfunction citing two RCTs but not applicable in the context of cancer [72] .
Enemas. In general, enemas are used only if oral treatment fails after several days and in order to prevent faecal impaction [2, 63] . Small volume self-administered enemas are commercially available and are often adequate. Larger volume clinicianadministered enemas should be administered by an experienced health professional [IV, C] [25] . The use of enemas involves risks of perforation of the intestinal wall (which should be anticipated and suspected if abdominal pain occurs), rectal mucosal damage and bacteraemia. Patients on therapeutic or prophylactic anticoagulation or who are affected by coagulation and platelet disorders are at risk of bleeding complications or intramural haematomas [73, 74] .
Contraindications to enemas in the treatment of constipation are presented in Table 7 . Table 8 presents a range of enemas commonly used in practice and the rationale for use. Evidence to support choice of one type of enema over another is limited.
Recommendations for the management of constipation:
• Best practice is based on a balance between strategies for prevention and self-care and prescribed oral and rectal laxative therapy [V, B].
• Key factors for prevention and self-care in the management of constipation include: ensuring privacy and comfort to allow a patient to defaecate normally; positioning (to assist gravity, a small footstool may help patient exert pressure more easily); increased fluid intake; increased activity and increased mobility within patient limits (even bed to chair); anticipatory management of constipation when opioids are prescribed [V, B].
• There is some evidence that abdominal massage can be efficacious in reducing gastrointestinal symptoms and improving Liquid paraffin A mineral oil that softens and lubricates the stools. Aspiration may cause lipoid pneumonia [93] , anal seepage, skin excoriation and a foreign body reaction if there is a break in the anorectal mucosa. Less effective than PEG OIC, opioid-induced constipation; PEG, polyethylene glycol. 
Management of faecal impaction
Faecal impaction is a complication of CC evidenced by a large mass of dry, hard stool in the rectum or proximal colon due to A relatively new anal irrigation system. Introduces water (500-700 mL) into the bowel using a rectal catheter and it is carried out while sitting on the toilet. Stimulates peristalsis and bowel emptying. Evidence for its use comes primarily from studies on neurogenic bowel dysfunction in patients with spinal cord injury and may not be practical in advanced disease [93] Invasive procedure. Needs close supervision to ensure safe administration CC [75] . Watery stool from higher in the bowel may leak (overflow). Diagnosis of faecal impaction is confirmed by DRE.
Where faecal impactions occur in the proximal rectum or sigmoid colon, DRE will be non-diagnostic. The treatment of a distal faecal impaction has not been the subject of clinical trials. Practice reports the utility of digital fragmentation of the stool, followed by enema (water or oil retention) or suppository to facilitate its passage through the anal canal. Once the distal colon has been partially emptied with disimpaction and enemas, PEG may be administered orally. In the case of proximal faecal impaction and in the absence of complete bowel obstruction, lavage with PEG solutions containing electrolytes may help to soften or wash out stool. Complications of faecal impaction, though uncommon, include urinary tract obstruction, perforation of the colon, dehydration, electrolyte imbalance, renal insufficiency, faecal incontinence, decubitus ulcers, stercoral ulcers and rectal bleeding [76, 77] .
Recommendation:
• In the absence of suspected perforation or bleed, the management of faecal impaction involves disimpaction (usually through digital fragmentation and extraction of the stool), followed by the implementation of a maintenance bowel regimen to prevent recurrence [V, B] [75] [76] [77] [78] .
Management of constipation in the elderly cancer patient
Aetiology. Ageing causes a degenerative process in the enteric nervous system. The effect of cancer and oncological treatments can be magnified, leading to a greater risk of severe constipation, faecal impaction and complications such as intestinal obstruction. Elderly patients with cancer represent a distinct subgroup at enhanced risk of constipation and its sequelae. The prevalence of constipation in the older adult ranges from 24% to 50% and laxatives are used daily by 10%-18% of community-dwelling older adults and 74% of nursing home residents [79, 80] .
The evidence for the management of constipation in the older person is notably based on expert opinion and therefore, although appropriate for best practice, further high-quality studies are required to support clinical practice. There are two points to note with specific reference to ageing:
Assessment. Particular attention should be paid to the assessment of elderly patients [V, B] . Noting all comorbidities, a complete medication list should be obtained. Withdrawal of inappropriate or unnecessary medications is important. Key factors include:
• A social history particularly focused on the patient's current living situation (living with family or alone; in a nursing home or in hospice) to understand timing and feasibility of ongoing assessment of bowel pattern and choice of best therapeutic strategy for the patient.
• Mobility and autonomy in activities of daily living [81] (risk for poor nutrition and lack of independence in toileting).
• Presence of cognitive impairment (caregiver involvement for reliable information and better patient cooperation and comfort during physical examination is crucial). Conclusions Figure 1 provides an algorithm of diagnosis and treatment of constipation in advanced illness. Constipation is a major management issue for cancer clinicians. There is a clinical imperative for oncologists to be familiar with the common causes of this problem, its evaluation and management strategies. The lack of robust studies and over-reliance on expert review and consensus means that this clinical area requires further ongoing clinical research investigation.
Methodology
These Clinical Practice Guidelines were developed in accordance with the ESMO standard operating procedures for Clinical Practice Guidelines development http://www.esmo.org/ Guidelines/ESMO-Guidelines-Methodology. The relevant literature has been selected by the expert authors. A summary of recommendations is shown in Table 9 . Levels of evidence (LoEs) and grades of recommendation (GoRs) given in this clinical practice guideline have been applied using the system shown in Table 10 . The LoEs and GoRs are adapted from the Infectious Diseases Society of America-United States Public Health Service Grading System. LoEs are reported on a scale from I to V, where I is applied when evidence from at least one large RCT of good methodological quality (low potential for bias) or meta-analyses of well-conducted randomised trials Clinical Practice Guidelines Annals of Oncology without heterogeneity is identified, and V is applied for studies without a control group, case reports and expert opinions. GoRs are described from A to E, where A represents strong evidence for efficacy with a substantial clinical benefit (and therefore strongly recommended) through to E, where there is strong evidence against efficacy or for adverse outcome and would never be recommended. Statements without grading were considered justified standard clinical practice by the experts and the ESMO Faculty. The review of evidence and writing of sub-sections for this CPG was assigned to each author as follows: CO provided the section on assessment and clinical management; DLC and MG revised the section on palliative care and older people; PJL reviewed the sections on non-pharmacological management and faecal impaction; FS revised the section on new mu opioid receptor antagonists; NIC, FS and PJL reviewed and revised the LoE and GoR where appropriate. All authors reviewed and consolidated the CPG in its entirety. NIC provided an earlier draft ESMO guideline on the management of constipation for the group to review and utilise as a template for this CPG. PJL collated each author's revised section into a revised CPG, which was reviewed and agreed by the team. Each author identified and sourced the literature for their respective section. All authors approved the final CPG.
